糖尿病动态临床实践指南系列研究之二:2型糖尿病药物治疗策略发展的关键证据总结OA

Objective To summarize the key evidence in the development of drug treatment strategies for type 2 diabetes mellitus(T2DM),and to provide an evidence-based roadmap for tailoring pharmacological strategies in patients with T2DM.Methods A systematic search of domestic and foreign databases,relevant guidelines websites,and T2DM guidelines and expert consensus organized by the society was conducted.The search time limit is from January 1,2010,to April 1,2024,and the update search is until April 1,2025.A series of guidelines with early publication,stable and timely update,clear use process of antihyperglycemic drugs and high clinical applicability of the guidelines were screened.Results Two guideline series compiled by the Chinese Diabetes Society and the American Diabetes Association were selected to summarize the development of drug treatment strategies for T2DM,and to summarize the key evidence.With the version updates,the overall development trend of the two guideline series is consistent:both of them pay more attention to individualized treatment and comprehensive management,from blood glucose oriented to outcome oriented,and the dual benefits of GLP-1RA,SGLT2i and other drugs hypoglycemic+cardiorenal protection are the key to promoting change.However,the two series differ in the timing of addressing cardiac and renal complications and weight management.Differences also exist in the details of first-line agent selection and the prioritization of cardiac and renal complications.Conclusion This study summarizes the key evidence in the development of drug treatment strategies for T2DM,and to promote the rational planning of drug treatment strategies for patients with T2DM by medical staff.